Prevalence of Osteoporosis in Korean Prostate Cancer Patients Who is Receiving LHRH Agonist and/or Anti-androgen Agent

AstraZeneca

Status: Completed

Conditions: Osteoporosis; Prostate Cancer

Study type: Observational

Funder types: Industry

Identifiers

NCT01025479

NIS-OKR-CAS-2009/1

Details and patient eligibility

About

Prevalence rate of osteoporosis and it's actual management condition in Prostate cancer patients who takes LHRH antagonist and anti androgen

Enrollment: 829 patients

Sex: Male

Volunteers: No Healthy Volunteers

Inclusion criteria

• pathologic confirmation of prostate cancer
• patients who are taking LHRH antagonist or anti- androgen or both of them within 6 months since starting.

Exclusion criteria

• patients who are hard to be analysed by limitation of chart record according to investigators'discretion
• patients who already have been registered in this study